Meldonium (Mildronate — Gamma-Butyrobetaine Hydroxylase Inhibitor)

1. Generic or Accepted Substance Name & Classifications

Accepted Name: Meldonium (Mildronate — Gamma-Butyrobetaine Hydroxylase Inhibitor)
Common Names, Synonyms & Classifications: Meldonium Dihydrate; Mildronate; THP; 3-(2,2,2-Trimethylhydrazinium)propionate
Section Classification: Group B — Pharmacological & Prohibited Performance-Enhancing Substances (PERF-B17)

2. Pharmacological Class

Metabolic Modulator; Reversible Gamma-Butyrobetaine Hydroxylase (BBOX1) & Carnitine Palmitoyltransferase-1 (CPT-1) Inhibitor

3. Mechanism of Action

Structural analogue of gamma-butyrobetaine (the precursor of L-carnitine). Meldonium competitively inhibits gamma-butyrobetaine hydroxylase and renal carnitine reabsorption, reducing intracellular free L-carnitine concentrations and limiting transport of long-chain acyl-CoAs into mitochondria via CPT-1. Under ischaemic conditions, this shifts myocardial energy metabolism from oxygen-expensive fatty acid beta-oxidation toward more oxygen-efficient glycolysis.

4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)

Pharmacological Effect: Partial suppression of mitochondrial long-chain fatty acid oxidation in ischaemic tissue. Anti-Doping & Clinical Reality: Added to the WADA Prohibited List (Category S4.4 Metabolic Modulators) on 1 January 2016 after widespread prevalence was detected in Eastern European athletes. High-quality peer-reviewed studies in healthy non-ischaemic athletes show minimal to zero validated ergogenic evidence, while suppressing endogenous carnitine transport impairs fatty-acid endurance substrate utilisation!

5. Quality of Scientific Evidence

Evidence Assessment: PROHIBITED METABOLIC MODULATOR (WADA S4.4) — Unapproved in India, US, and EU; Lacks Rigorous Ergogenic Evidence in Healthy Athletes

6. Approved Medical Uses (Where Applicable)

Manufactured in Latvia and registered only in a limited number of Eastern European/CIS countries as an adjunctive anti-ischaemic medicine. NOT approved by CDSCO (India), US FDA, EMA, or UK MHRA for any medical indication.

7. Sports-Related Uses, Misuse Patterns & Contamination Risks

Historically misused in endurance and racket sports under the belief that it improved oxygen economy and post-exercise recovery. Exhibits biphasic elimination kinetics where trace urinary excretion from erythrocytes/tissues can persist for several months after multi-week administration, resulting in numerous anti-doping sanctions.

8. Adverse Effects & Serious Safety Risks

Tachycardia, blood pressure fluctuations (hypotension or hypertension), dyspepsia, agitation, allergic skin rashes, eosinophilia, and theoretical hepatic steatosis/myopathic fatigue from chronic carnitine depletion.

9. Contraindications & Precautions

Unapproved for clinical use in India; contraindicated in intracranial hypertension, severe hepatic or renal insufficiency, pregnancy, lactation, and all WADA-governed sports.

10. Drug Interactions

Potentiates the hypotensive and vasodilatory effects of Nitroglycerin, Nifedipine, beta-blockers, and peripheral vasodilators.

11. Clinical & Laboratory Monitoring Considerations

Not a licensed medicine in India; competitive athletes must never ingest unlicensed imported Eastern European metabolic preparations.

12. Dependence, Misuse or Withdrawal Concerns

No known classical neurochemical addiction.

13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)

UNAPPROVED DRUG in India (Not approved by CDSCO and not included in the Indian Pharmacopoeia IP 2022 or NLEM 2022).

14. Official WADA Prohibited-List Status

PROHIBITED AT ALL TIMES (In-Competition and Out-of-Competition) under WADA Prohibited List Category S4.4 (Metabolic Modulators — Non-Specified Substance, alongside Trimetazidine and GW501516).

15. Authoritative Source References & Date of Last Verification